Transaction in Own Shares

| Source: Novo Nordisk A/S Novo Nordisk A/S

At Novo Nordisk's ordinary general meeting on the 7 March 2007 it was decided to reduce the company's B-share capital from DKK 566,432,800 to DKK 539,472,800 by cancellation of part of the company's portfolio of own B shares at a nominal value of DKK 26,960,000 divided into 13,480,000 B shares of DKK 2 each.
 
Today, Novo Nordisk has registered the final implementation of the reduction of the share capital with the Danish Commerce and Companies Agency and cancelled nominally DKK 26,960,000 B shares. After the reduction of the share capital, the company's share capital is nominally DKK 646,960,000, which is divided into an A share capital of nominally DKK 107,487,200 and a B share capital of nominally DKK 539,472,800.
 
Holding of own shares
In the company's stock exchange announcement no 8/2007 of 3 April 2007 it was stated that Novo Nordisk A/S (NYSE: NVO) and its wholly-owned affiliates as per 31 March 2007 owned 19,163,309 of its own B shares of DKK 2, corresponding to a total nominal value of DKK 38,326,618 or 5.69% of the total share capital.
 
Since 3 April 2007 a total of 138,000 B shares have been repurchased by Novo Nordisk A/S, and 306,625 B shares have been disposed of to employees who have exercised options granted by Novo Nordisk.
 
Following the cancellation of nominally DKK 26,960,000 (13,480,000 shares) of the company's own B shares and pursuant to Section 28 of the Danish securities Trading Act, it is hereby announced that Novo Nordisk A/S and its wholly-owned affiliates as per 19 June 2007 own 5,514,684 of its own B shares. This corresponds to a total nominal value of DKK 11,029,368 B-shares or 1.7% of the total share capital.
 
Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 23.600 full-time employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.
 
Further information:
 
Stock Exchange Announcement no 16 / 2007